top of page

Topic

Carcinoma in Situ (CIS)

6 Podcasts • 2 Courses on BackTable

Hear how experienced physicians manage Carcinoma in Situ (CIS) on BackTable. Learn from podcasts, cases, and courses curated by physician content creators, covering diagnosis, clinical decision-making, and treatments. Get the BackTable app to follow this Topic and hear more of the conversations that matter to your practice.

Bladder Cancer Risk Stratification: Best Practices
00:00 / 01:04

Save your progress. Continue watching on the BackTable app.

BackTable Tumor Board

Episode # 67  •  18 Jun 2026

Bladder Cancer Risk Stratification: Best Practices

Why does up to 10% of bladder cancer pathology change on expert review, and what does that mean for your intermediate and high-risk patients? In this episode of BackTable, Dr. Bogdana Schmidt interviews urologists Dr. Kristen Scarpato and Dr. Sunil Patel to explore the complexities of diagnosis and risk assessment in non–muscle invasive bladder cancer (NMIBC). They discuss the real-world challenges of pathology interpretation, risk-group assignment, evolving diagnostic tools, and the impact these factors have on treatment decisions and patient outcomes.

This podcast is supported by an educational grant from Johnson & Johnson.

More on Carcinoma in Situ (CIS)

Loading recent podcasts…

Tumor Board

Tumor Board # 67

Jun 17, 2026

with Dr. Sunil Patel, Dr. Kristen Scarpato, Dr. Bogdana Schmidt

Bladder Cancer Risk Stratification: Best Practices

Why does up to 10% of bladder cancer pathology change on expert review, and what does that mean for your intermediate...

Urology

Urology # 268

Oct 23, 2025

with Dr. Tyler Stewart, Dr. Bogdana Schmidt

Non-Muscle Invasive Bladder Cancer: Role of Medical Oncology

With the introduction of checkpoint inhibitors into non-muscle invasive bladder cancer (NMIBC) management, who’s on...

1,200+ listens

Tumor Board

Tumor Board # 27

Oct 6, 2025

with Dr. Tyler Stewart, Dr. Bogdana Schmidt

Non-Muscle Invasive Bladder Cancer: Role of Medical Oncology

With the introduction of checkpoint inhibitors into non-muscle invasive bladder cancer (NMIBC) management, who’s on...

Urology

Urology # 271

Nov 6, 2025

with Dr. Katie Murray, Dr. Sarah Psutka, Dr. Vignesh Packiam

How Biomarkers Enhance Precision Medicine in Non-Muscle Invasive Bladder Cancer

As new genetic and AI-powered tools emerge for bladder cancer screening, are we getting closer to reducing the need for...

1,400+ listens

Urology

Urology # 264

Oct 9, 2025

with Dr. Anne Schuckman, Dr. Piyush Agarwal, Dr. Bogdana Schmidt

Contemporary Diagnostics in NMIBC: Clinical Insights

How are leading urologic oncologists using advanced biomarkers and artificial intelligence to refine the diagnosis and...

1,300+ listens

Urology

Urology # 64

Nov 8, 2022

with Dr. Timothy Clinton, Dr. Eugene Pietzak, Dr. Aditya Bagrodia

Management of BCG-refractory NMIBC

In this episode of BackTable Urology, Dr. Aditya Bagrodia speaks with two fellow urologic oncologists, Dr. Timothy...

2,500+ listens

The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.

bottom of page